Haldol

Haldol is the brand name for the injectable solution of haloperidol, a butyrophenone antipsychotic marketed in the European Union. It is supplied as a sterile intramuscular preparation intended for single or repeated dosing and is classified as a prescription‑only medication. The product is listed under ATC code N05AD01 and works as a dopamine D2 receptor antagonist and is used under medical supervision in hospital or outpatient settings.

Haloperidol injectable solution is prescribed for the short‑term control of acute psychiatric symptoms that require rapid onset of action, particularly when oral administration is not feasible.

- Schizophrenia with sudden worsening of symptoms or severe agitation requiring intramuscular therapy. - Acute psychotic episodes in adults, including first‑episode psychosis. - Intense agitation or violent behavior associated with psychotic disorders. - Pre‑operative sedation for patients who cannot be calmed with oral agents. - Management of delirium in hospitalised patients when oral antipsychotics are unsuitable. - Acute mania or mixed episodes in bipolar disorder when rapid intramuscular control is required.

Like other antipsychotics, haloperidol injectable solution can produce a range of adverse effects that vary in frequency and severity.

Common: - Drowsiness or sedation, which may affect alertness and the ability to operate machinery. - Extrapyramidal symptoms such as tremor, muscle rigidity, akathisia (restlessness), or dystonia, often occurring early in treatment. - Dry mouth and increased salivation, reflecting anticholinergic effects on oral secretions. - Constipation or other gastrointestinal discomfort, which may require dietary adjustments.

Serious: - Neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by high fever, muscle rigidity, autonomic instability, and altered mental status. - Cardiac arrhythmias including torsade de pointes or prolonged QT interval, which can lead to serious rhythm disturbances. - Severe hypotension or syncope, especially after rapid intramuscular injection, requiring monitoring of blood pressure.

When prescribing haloperidol injectable solution, clinicians should consider several precautionary measures to minimize risks and ensure safe use.

- Assess for a history of cardiovascular disease, as haloperidol may prolong the QT interval. - Evaluate for prior extrapyramidal reactions or movement disorders before initiating therapy. - Use caution in patients with hepatic or renal impairment, adjusting dose as needed. - Monitor for signs of neuroleptic malignant syndrome, especially early in treatment. - Avoid use in patients with known hypersensitivity to haloperidol or other butyrophenones. - Consider sedation risk when combined with other CNS depressants.

Haloperidol injectable solution can interact with other medications, influencing its efficacy or safety profile.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which may increase the risk of extrapyramidal side effects. - Medications that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics), due to additive cardiac risk. - Strong CYP3A4 inhibitors (such as ketoconazole or clarithromycin) that can raise haloperidol plasma concentrations.

Use with caution: - CNS depressants including benzodiazepines, opioids, or alcohol, which may enhance sedation and respiratory depression. - Antihypertensive agents, because haloperidol can cause orthostatic hypotension. - Drugs affecting hepatic metabolism (e.g., carbamazepine) that may reduce haloperidol levels.